A randomized, phase III trial to determine the effect of consolidation with rituximab (IDEC C2B8-Mabthera) in patients with CD20+ follicular or mantle cell lymphoma having received induction therapy with rituximab weekly x 4.
Phase of Trial: Phase III
Latest Information Update: 06 Aug 2011
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- 11 Nov 2009 Status changed from active, no longer recruiting to completed.
- 12 Oct 2009 Long-term follow-up results presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
- 30 May 2009 Results presented at ASCO 2009.